These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16171895)

  • 1. Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches.
    Yeung E; Chung RT
    J Hepatol; 2005 Nov; 43(5):748-50. PubMed ID: 16171895
    [No Abstract]   [Full Text] [Related]  

  • 2. [Genotype 1 superresponder treat for only 24 weeks].
    MMW Fortschr Med; 2005 Dec; 147(51-52):69. PubMed ID: 16402717
    [No Abstract]   [Full Text] [Related]  

  • 3. [Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
    Szalay F
    Orv Hetil; 2010 Feb; 151(7):271-3. PubMed ID: 20133247
    [No Abstract]   [Full Text] [Related]  

  • 4. Delaying HCV treatment in HIV-positive patients.
    Carter M
    IAPAC Mon; 2005 May; 11(5):147. PubMed ID: 16201045
    [No Abstract]   [Full Text] [Related]  

  • 5. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 6. HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2282-3. PubMed ID: 17570197
    [No Abstract]   [Full Text] [Related]  

  • 7. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon for hepatitis C patients with psychiatric disorders.
    Rifai MA; Bozorg B; Rosenstein DL
    Am J Psychiatry; 2004 Dec; 161(12):2331-2; author reply 2332-4. PubMed ID: 15569919
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of HBV/HCV coinfection: releasing the enemy within.
    Gordon SC; Sherman KE
    Gastroenterology; 2009 Feb; 136(2):393-6. PubMed ID: 19105960
    [No Abstract]   [Full Text] [Related]  

  • 10. Super-infection with genotype 4 hepatitis C virus in a patient treated for genotype 3 acute hepatitis C.
    Loulergue P; Mir O; Sogni P
    AIDS; 2012 Mar; 26(5):655-6. PubMed ID: 22398573
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel therapies in Hepatitis C virus. Preface.
    Pockros PJ
    Clin Liver Dis; 2009 Aug; 13(3):xiii. PubMed ID: 19628152
    [No Abstract]   [Full Text] [Related]  

  • 12. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to issues raised in the Jansen/Reesink editorial.
    Silva M
    J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
    [No Abstract]   [Full Text] [Related]  

  • 15. The end of the beginning for hepatitis C treatment.
    Dieterich D
    Hepatology; 2012 Mar; 55(3):664-5. PubMed ID: 22174100
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of chronic hepatitis C].
    Fehér J; Lengyel G
    Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
    [No Abstract]   [Full Text] [Related]  

  • 17. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 19. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
    Foruny JR; Bárcena R; Moreno A; Blázquez J; Manzano R; Gil-Grande LA; Moreno A; Nuño J
    Transplantation; 2006 Jul; 82(2):289-90. PubMed ID: 16858295
    [No Abstract]   [Full Text] [Related]  

  • 20. PegIFN/ribavirin during acute HCV coinfection.
    Bernard EJ
    IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.